mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study

Eric Yuk Fai Wan, Celine Sze Ling Chui, Anna Hoi Ying Mok, Wanchun Xu, Vincent Ka Chun Yan, Francisco Tsz Tsun Lai, Xue Li, Carlos King Ho Wong, Esther Wai Yin Chan, David Tak Wai Lui, Kathryn Choon Beng Tan, Ivan Fan Ngai Hung, Cindy Lo Kuen Lam, Gabriel Matthew Leung and Ian Chi Kei Wong ()
Additional contact information
Eric Yuk Fai Wan: The University of Hong Kong
Celine Sze Ling Chui: Hong Kong Science and Technology Park
Anna Hoi Ying Mok: The University of Hong Kong
Wanchun Xu: The University of Hong Kong
Vincent Ka Chun Yan: The University of Hong Kong
Francisco Tsz Tsun Lai: The University of Hong Kong
Xue Li: The University of Hong Kong
Carlos King Ho Wong: The University of Hong Kong
Esther Wai Yin Chan: The University of Hong Kong
David Tak Wai Lui: The University of Hong Kong
Kathryn Choon Beng Tan: The University of Hong Kong
Ivan Fan Ngai Hung: The University of Hong Kong
Cindy Lo Kuen Lam: The University of Hong Kong
Gabriel Matthew Leung: Hong Kong Science and Technology Park
Ian Chi Kei Wong: The University of Hong Kong

Drug Safety, 2022, vol. 45, issue 12, No 4, 1477-1490

Abstract: Abstract Introduction In Hong Kong, CoronaVac and BNT162b2 have been approved for emergency use owing to the coronavirus disease 2019 (COVID-19) pandemic. Reactions towards the vaccine and the risk of post-vaccination adverse events may be different between recipients with and without type 2 diabetes mellitus (T2DM). Objective The aim of this study was to evaluate the risk of adverse events of special interest (AESI) and acute diabetic complications in the T2DM population after COVID-19 vaccination in Hong Kong. Research Design and Methods Self-controlled case-series analysis was conducted. Patients with T2DM who received at least one dose of BNT162b2 or CoronaVac between 23 February 2021 and 31 January 2022 from electronic health records in Hong Kong were included. The incidence rates of 29 AESIs and acute diabetic complications (any of severe hypoglycemia, diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome) requiring hospitalization within 21 days after the first or second dose of vaccination were reported. The risks of these outcomes were evaluated using conditional Poisson regression. Results Among 141,224 BNT162b2 recipients and 209,739 CoronaVac recipients with T2DM, the incidence per 100,000 doses and incidence per 100,000 person-years of individual AESIs and acute diabetic complications ranged from 0 to 24.4 and 0 to 438.6 in BNT162b2 group, and 0 to 19.5 and 0 to 351.6 in CoronaVac group. We did not observe any significantly increased risk of individual AESIs or acute diabetic complications after first or second doses of BNT162b2 or CoronaVac vaccine. Subgroup analysis based on HbA1c

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-022-01228-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:45:y:2022:i:12:d:10.1007_s40264-022-01228-6

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-022-01228-6

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().